Holen Sie sich die Stockscreener-App
174.10
0.93%
1.60
Handel nachbörslich:
172.60
-1.50
-0.86%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BIIB?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$172.50
Offen:
$173.49
24-Stunden-Volumen:
1.75M
Relative Volume:
0.97
Marktkapitalisierung:
$25.54B
Einnahmen:
$9.61B
Nettoeinkommen (Verlust:
$1.53B
KGV:
16.66
EPS:
10.453
Netto-Cashflow:
$1.85B
1W Leistung:
-3.97%
1M Leistung:
+7.82%
6M Leistung:
+31.58%
1J Leistung:
+12.08%
1-Tages-Spanne:
$171.27
$175.08
1-Wochen-Bereich:
$169.24
$182.12
52-Wochen-Spanne:
$110.03
$185.17
Biogen Inc Stock (BIIB) Company Profile
Firmenname
Biogen Inc
Sektor
Telefon
(781) 464-2000
Adresse
225 BINNEY STREET, CAMBRIDGE, MA
Vergleichen Sie BIIB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
174.10 | 25.31B | 9.61B | 1.53B | 1.85B | 10.45 |
|
LLY
Lilly Eli Co
|
1,027.51 | 903.41B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
211.58 | 505.98B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
223.32 | 395.86B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
132.57 | 253.97B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
100.30 | 245.75B | 63.90B | 19.05B | 13.05B | 7.5596 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-10 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2025-11-06 | Hochstufung | Stifel | Hold → Buy |
| 2025-09-25 | Eingeleitet | Jefferies | Buy |
| 2025-07-21 | Fortgesetzt | Truist | Hold |
| 2025-04-28 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-04-04 | Herabstufung | Argus | Buy → Hold |
| 2025-02-11 | Eingeleitet | Bernstein | Mkt Perform |
| 2025-01-02 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-12-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-16 | Herabstufung | Stifel | Buy → Hold |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-12-09 | Herabstufung | Jefferies | Buy → Hold |
| 2024-11-18 | Herabstufung | Needham | Buy → Hold |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-14 | Eingeleitet | Citigroup | Neutral |
| 2024-10-31 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-02-14 | Bestätigt | Needham | Buy |
| 2024-02-14 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | Herabstufung | UBS | Buy → Neutral |
| 2023-12-20 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-12-07 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | Eingeleitet | HSBC Securities | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-07-24 | Bestätigt | UBS | Buy |
| 2023-05-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-04-17 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | Hochstufung | Goldman | Neutral → Buy |
| 2022-10-13 | Hochstufung | Stifel | Hold → Buy |
| 2022-10-07 | Hochstufung | Argus | Hold → Buy |
| 2022-09-28 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | Hochstufung | Mizuho | Neutral → Buy |
| 2022-09-28 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | Herabstufung | Stifel | Buy → Hold |
| 2022-03-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | Bestätigt | Barclays | Equal Weight |
| 2022-02-04 | Bestätigt | BofA Securities | Neutral |
| 2022-02-04 | Bestätigt | Cowen | Outperform |
| 2022-02-04 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-04 | Bestätigt | Needham | Buy |
| 2022-02-04 | Bestätigt | Oppenheimer | Outperform |
| 2022-02-04 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | Bestätigt | Robert W. Baird | Neutral |
| 2022-02-04 | Bestätigt | Wedbush | Neutral |
| 2022-02-04 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-02-04 | Bestätigt | Wolfe Research | Peer Perform |
| 2022-01-13 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-01-12 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-09-23 | Eingeleitet | Needham | Buy |
| 2021-06-18 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | Bestätigt | Truist | Buy |
| 2021-06-11 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | Hochstufung | UBS | Neutral → Buy |
| 2021-06-08 | Hochstufung | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | Bestätigt | Barclays | Equal Weight |
| 2021-06-08 | Hochstufung | Citigroup | Sell → Neutral |
| 2021-06-08 | Bestätigt | H.C. Wainwright | Buy |
| 2021-06-08 | Bestätigt | Jefferies | Buy |
| 2021-06-08 | Bestätigt | Morgan Stanley | Overweight |
| 2021-06-08 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | Hochstufung | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | Bestätigt | Stifel | Buy |
| 2021-06-08 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-06-07 | Hochstufung | Cowen | Market Perform → Outperform |
| 2021-06-07 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | Herabstufung | DZ Bank | Buy → Hold |
| 2021-01-29 | Hochstufung | Stifel | Hold → Buy |
| 2020-11-10 | Hochstufung | DZ Bank | Hold → Buy |
| 2020-11-09 | Herabstufung | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-11-09 | Herabstufung | Cowen | Outperform → Market Perform |
| 2020-11-09 | Bestätigt | H.C. Wainwright | Buy |
| 2020-11-04 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2020-11-04 | Hochstufung | Jefferies | Hold → Buy |
| 2020-11-04 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-07-27 | Hochstufung | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2020-06-22 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | Herabstufung | Citigroup | Neutral → Sell |
| 2020-04-23 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2020-01-27 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | Herabstufung | Robert W. Baird | Neutral → Underperform |
Alle ansehen
Biogen Inc Aktie (BIIB) Neueste Nachrichten
Biogen: Alzheimer's Disease Treatment Needs More Real-World Data (NASDAQ:BIIB) - Seeking Alpha
Hudson Bay Capital Management LP Buys 67,220 Shares of Biogen Inc. $BIIB - MarketBeat
Hudson Bay Capital Management LP Has $33.63 Million Position in Biogen Inc. $BIIB - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
Lululemon, Biogen to exit Nasdaq 100 with Alnylam, Seagate among additions - Seeking Alpha
Biogen Inc. $BIIB Shares Purchased by Balyasny Asset Management L.P. - MarketBeat
Nasdaq says Biogen, CDW Corporation, GlobalFoundries, Lululemon Athletica, On Semiconductor, Trade Desk will be removed from Nasdaq 100 index - marketscreener.com
Key facts: Biogen to release tau drug data; Morgan Stanley raises target; Jefferies hints at Nasdaq 100 removal - TradingView
Tiziana Life Sciences to Dose First Patient in Phase 2 Alzheimer’s Trial - GlobeNewswire Inc.
Biogen (BIIB) Sees Target Price Increase by Morgan Stanley | BII - GuruFocus
Morgan Stanley Adjusts Biogen Price Target to $156 From $149, Maintains Equalweight Rating - marketscreener.com
Boards of Appeal revoke Biogen’s dosage patent for Tecfidera - JUVE Patent
Alzheimer's drug hunt learns from cancer fight's multi-target playbook - marketscreener.com
State Street Corp Raises Position in Biogen Inc. $BIIB - MarketBeat
United States Controlled Release Drug Delivery Market to Reach - openPR.com
Axa S.A. Sells 45,397 Shares of Biogen Inc. $BIIB - MarketBeat
Biogen Inc (NASDAQ:BIIB) Nasdaq Composite ETF Neuro Innovation - Kalkine Media
Forecast 2035: Alzheimers Disease Diagnostic Market Size Set - openPR.com
Biogen (BIIB) Is Down 5.2% After HSBC Downgrade Amid Mixed Drug Pipeline Signals – Has The Bull Case Changed? - simplywall.st
Canadian HTA Assessments Recognize Therapeutic Value of QALSODY™ (tofersen injection) and its Potential to Modify Disease Progression in Individuals Living with SOD1-ALS - BioSpace
Federated Hermes Inc. Acquires 17,069 Shares of Biogen Inc. $BIIB - MarketBeat
Why Analysts See Biogen’s Story Shifting Toward Undervalued Growth Potential - Yahoo Finance
Wells Fargo Maintains Biogen (BIIB) Equal-Weight Recommendation - Nasdaq
BIIB: Analyst Raises Price Target, Maintains Equal-Weight Rating - GuruFocus
Biogen (BIIB) Downgraded by HSBC Amid Growth Concerns - GuruFocus
AbbVie upgraded, Biogen downgraded as HSBC reflects on 2026 in pharma - MSN
AbbVie upgraded, Biogen downgraded at HSBC (BIIB:NASDAQ) - Seeking Alpha
Biogen (NASDAQ:BIIB) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says - MarketBeat
Here are Wednesday’s top Wall Street analyst research calls: AbbVie, Amazon.com, Biogen, EchoStar, Ferrari, GE Vernova, PepsiCo, Take-Two Interactive, and more - MSN
Here Are Wednesday’s Top Wall Street Analyst Research Calls: AbbVie, Amazon.com, Biogen, EchoStar, Ferrari, GE Vernova, PepsiCo, Take-Two Interactive, and More - Yahoo Finance
This Biogen Analyst Turns Bearish; Here Are Top 4 Downgrades For Wednesday - Benzinga
Here Are Wednesday's Top Wall Street Analyst Research Calls: AbbVie, Amazon.com, Biogen, EchoStar, Ferrari, GE Vernova, PepsiCo, Take-Two Interactive, and More - 24/7 Wall St.
Wells Fargo Adjusts Price Target on Biogen to $190 From $155, Maintains Equalweight Rating - marketscreener.com
HSBC Downgrades Biogen (BIIB) with New Target Price | BIIB Stock News - GuruFocus
Biogen Receives Health Canada Authorization for ZURZUVAE™ (zuranolone), the First and Only Treatment Indicated for Adults with Postpartum Depression in Canada - BioSpace
Analyst recommendations: Abbvie, Biogen, PepsiCo, Eli Lilly, Netflix… - marketscreener.com
HSBC Downgrades Biogen to Reduce From Hold, Adjusts Price Target to $143 From $144 - marketscreener.com
California Public Employees Retirement System Sells 46,044 Shares of Biogen Inc. $BIIB - MarketBeat
HSBC downgrades Biogen stock rating to Reduce on royalty concerns - Investing.com
Is Biogen’s Recent 20% Rally Just the Start as Valuation Signals Turn Attractive? - simplywall.st
Biogen Inc. Stock Underperforms Tuesday When Compared To Competitors - 富途牛牛
symbol__ Stock Quote Price and Forecast - CNN
Marshall Wace LLP Boosts Holdings in Biogen Inc. $BIIB - MarketBeat
Biogen (SUPN) gains Health Canada NOC for ZURZUVAE in postpartum depression treatment - Stock Titan
Amundi Cuts Position in Biogen Inc. $BIIB - MarketBeat
Eisai and Biogen's LEQEMBI® Added to China's Commercial Insurance Innovative Drug List, Enhancing Access to Alzheimer's Treatment - Quiver Quantitative
“LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Included in China’s Commercial Insurance Innovative Drug List - Biogen
Biogen (BIIB): Assessing Valuation After Promising New Zorevunersen Data in Dravet Syndrome - simplywall.st
Will Cobenfy Become a Growth Driver for BMY's Neuroscience Business? - The Globe and Mail
Is Biogen Stock Outperforming the Dow? - Barchart.com
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI(R) (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at CTAD 2025 - marketscreener.com
Finanzdaten der Biogen Inc-Aktie (BIIB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.37%
0.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):